product name Piracetam
Description: Piracetam (also known as UCB 6215) is a cyclic derivative of the neurotransmitter gamma-aminobutyric acid (GABA) used in treatment of a wide range of cognitive disorders. Piracetam is considered to be both a nootropic and a neuroprotective agent. Piracetam is a positive allosteric modulator of the AMPA receptor. It is believed to act on ion channels or ion carriers, thus leading to increased neuron excitability.
References: Biochim Biophys Acta. 2003 Jan 10;1609(1):28-38; Biochem Pharmacol. 1997 Jan 24;53(2):135-40.
142.16
Formula
C6H10N2O2
CAS No.
7491-74-9
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 72 mg/mL (506.5 mM)
Water: 72 mg/mL (506.5 mM)
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
UCB 6215
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19423552
| In Vitro |
In vitro activity: Piracetam is able to significantly decrease the fusogenic and destabilising effect of Abeta 29-42, in a concentration-dependent manner. Preincubation of piracetam, at a piracetam/peptide ratio of 960, during 20 min before the addition of Abeta 29-42 prevents almost completely the mixture of the two fluorescent probes. Preincubation of piracetam with lipids prevents almost completely the release of calcein induced by the peptide in a dose-dependent fashion (piracetam/peptide ratios from 9.6 to 960). Piracetam (< 1.0 mM) preincubated with brain membranes enhances membrane fluidity in aged mice, rats and humans, as indicated by decreased anisotropy of the membrane-bound fluorescence probe 1,6-diphenyl-1,3,5-hexatriene (DPH). Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Piracetam (300 mg/kg once daily) significantly increases membrane fluidity in some brain regions of young and aged rats, but has no measurable effect on membrane fluidity in the young rats. Piracetam (300 mg/kg daily for 6 weeks) improves active avoidance learning in the aged rats only and elevates membrane fluidity in all brain regions except the cerebellum in the aged rats. Piracetam (300 mg/kg daily for 6 weeks) also improves NMDA receptor density in the hippocampus and on muscarinic cholinergic receptor densities in the frontal cortex and the striatum and to a lesser extent in the hippocampus of rats. Piracetam (500 mg/kg p.o. for 14 days) elevates N-methyl-D-aspartate (NMDA) receptor density by about 20% and normalizes the enhanced affinity of L-glutamate for the NMDA receptor in aged mice. Piracetam-treated withdrawn rats has higher the number of synapses than that observed in nonpiracetam-treated and alcohol-fed animals by up to 20%, the mechanisms leading to the synaptic reorganization took place at the mossy fiber level. |
| Animal model | Male Wistar rats |
| Formulation & Dosage | Dissolved in saline; 300 mg/kg; oral gavage |
| References | Biochem Pharmacol. 1997 Jan 24;53(2):135-40; Pharmacopsychiatry. 1999 Mar;32 Suppl 1:10-6; Pharmacology. 1993 Oct;47(4):217-22. |
